StockNews.AI
HIMS
StockNews.AI
49 days

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Hims & Hers Health, Inc. (NYSE: HIMS) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

1. Edelson Lechtzin LLP is investigating Hims for potential securities law violations. 2. Hims may have provided misleading business information to investors. 3. Novo Nordisk ended its partnership with Hims due to compliance concerns. 4. Following the termination, Hims' stock price plummeted by 34.63%. 5. Investors may seek compensation for losses incurred from stock decline.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The termination of a major partnership caused a significant stock price drop, indicating investor lack of confidence.

How important is it?

The ongoing investigation and stock price drop directly affect Hims' market perception and investor trust.

Why Short Term?

Immediate concerns about compliance issues may lead to further scrutiny and volatility in the stock price.

Related Companies

NVO
NEWTOWN, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Hims & Hers Health, Inc. (“Hims”) (NYSE: HIMS), resulting from allegations of providing potentially misleading business information to the investing public. If you would like to speak with an attorney about the Hims investigation and the potential recovery of your investment losses, please provide your information HERE. You can also contact attorney Eric Lechtzin of Edelson Lechtzin LLP by calling 844-563-5550 or via e-mail at elechtzin@edelson-law.com. THE COMPANY: Hims is a telehealth and online pharmacy company that offers prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform, connecting users with licensed healthcare professionals in the U.S. and the U.K. THE ALLEGED WRONGDOING: On April 29, 2025, multinational pharmaceutical company Novo Nordisk announced that it would sell its weight loss drug Wegovy through Hims’ telehealth platform. On June 23, 2025, Novo Nordisk terminated its partnership with Hims, citing concerns about Hims’ compliance with laws governing the sale and marketing of compounded drugs. On this news, Hims’ stock price fell $22.24 per share, or 34.63%, to close at $41.98 per share on June 23, 2025. ABOUT EDELSON LECHTZIN LLP: Edelson Lechtzin LLP is a national class action law firm with offices in Philadelphia and San Francisco. In addition to cases involving securities and investment fraud, our lawyers focus on class action cases alleging violations of federal antitrust laws, employee benefit plans under ERISA, wage theft, data security breaches, and consumer fraud. For more information, please contact: Marc H. Edelson, Esq.Eric Lechtzin, Esq.EDELSON LECHTZIN LLP411 S. State Street, Suite N-300Newtown, PA 18940Phone: 844-696-7492 or 215-867-2399 ext. 1 Email: medelson@edelson-law.comEmail: elechtzin@edelson-law.com   Web: www.edelson-law.com This press release may be considered Attorney Advertising in some jurisdictions. No class has been certified in this case, so you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. Your ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Related News